Scottish Medicines Consortium dexamethasone (Neofordex)

Scottish Medicines Consortium dexamethasone (Neofordex)

in the absence of a submission from the holder of the marketing authorisation:

dexamethasone (Neofordex®) is not recommended for use within NHS Scotland.

Indication under review: In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Name: dexamethasone (Neofordex)
SMC Drug ID: 1322/18
Manufacturer: Aspire Pharma Ltd
Indication: In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 March 2018

 

To read more Press Release articles, click here.